Defining preclinical efficacy with the DNAPK inhibitor AZD7648 in combination with olaparib: a minimal systems pharmacokinetic–pharmacodynamic model.

Therapeutic area :

DeJong J., Cadogan E., Davies M., Ramos-Montoya A., Smith A., Steeg van T.J., Richards R. Defining preclinical efficacy with the DNAPK inhibitor AZD7648 in combination with olaparib: a minimal systems pharmacokinetic–pharmacodynamic model. Journal of Pharmacokinetics and Pharmacodynamics 2025 [Link to publication].